Cargando…

Technical know‐how in stereotactic ablative radiotherapy (SABR)

Stereotactic ablative radiotherapy (SABR) is an addition to the armamentarium against cancer. The technical requirements for SABR are very stringent, given its very narrow therapeutic window. However, when the principles are strictly followed, it is possible to deliver SABR to extracranial tumours s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lo, Simon S., Foote, Matthew, Siva, Shankar, Slotman, Ben J., Teh, Bin S., Guckenberger, Matthias, Tan, Daniel, Mayr, Nina A., Sahgal, Arjun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775826/ https://www.ncbi.nlm.nih.gov/pubmed/27087969 http://dx.doi.org/10.1002/jmrs.163

Ejemplares similares

Radiobiology of stereotactic ablative radiotherapy (SABR): perspectives of clinical oncologists
por: Li, Shan, et al.
Publicado: (2020)

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial
por: David, Steven, et al.
Publicado: (2019)

Stereotactic Body Radiotherapy for Oligometastatic Disease in Non-small Cell Lung Cancer
por: Wujanto, Caryn, et al.
Publicado: (2019)

Stereotactic ablative body radiotherapy (SABR) for primary and secondary lung tumours
por: Goldsmith, Christy, et al.
Publicado: (2012)

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5
por: Olson, Robert, et al.
Publicado: (2018)

Quantification of interplay and gradient effects for lung stereotactic ablative radiotherapy (SABR) treatments
por: Tyler, Madelaine K.
Publicado: (2016)

Stereotactic ablative radiotherapy (SABR) for recurrent and previously irradiated head and neck cancers
por: Anand, Anil Kumar, et al.
Publicado: (2020)

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
por: Palma, David A, et al.
Publicado: (2012)

Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma?
por: Rühle, Alexander, et al.
Publicado: (2019)

Diffusion weighted and dynamic contrast enhanced MRI as an imaging biomarker for stereotactic ablative body radiotherapy (SABR) of primary renal cell carcinoma
por: Reynolds, Hayley M., et al.
Publicado: (2018)

Survey of current practices from an international task force for gynecological stereotactic ablative radiotherapy
por: Leung, E., et al.
Publicado: (2020)

Restricted bowel loop contouring: Improving efficiency in radiotherapy contouring for abdomino-pelvic Stereotactic Ablative Radiotherapy (SABR)
por: Clarke, Eleanor, et al.
Publicado: (2020)

Clinical evaluation of an endorectal immobilization system for use in prostate hypofractionated Stereotactic Ablative Body Radiotherapy (SABR)
por: Nicolae, Alexandru, et al.
Publicado: (2015)

Optimal and actual rates of Stereotactic Ablative Body Radiotherapy (SABR) utilisation for primary lung cancer in Australia
por: Ghandourh, Wsam, et al.
Publicado: (2022)

Hypofractionated image-guided breath-hold SABR (Stereotactic Ablative Body Radiotherapy) of liver metastases – clinical results
por: Boda-Heggemann, Judit, et al.
Publicado: (2012)

Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach
por: Comito, Tiziana, et al.
Publicado: (2014)

Time course and predictive factors for lung volume reduction following stereotactic ablative radiotherapy (SABR) of lung tumors
por: Binkley, Michael S., et al.
Publicado: (2016)

HIF-1α Inhibition Improves Anti-Tumor Immunity and Promotes the Efficacy of Stereotactic Ablative Radiotherapy (SABR)
por: Song, Chang W., et al.
Publicado: (2022)

Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial
por: Palma, David A., et al.
Publicado: (2019)

Technical Note: Dosimetric evaluation of Monte Carlo algorithm in iPlan for stereotactic ablative body radiotherapy (SABR) for lung cancer patients using RTOG 0813 parameters
por: Pokhrel, Damodar, et al.
Publicado: (2015)

Volumetric modulated arc therapy (VMAT) comparison to 3D‐conformal technique in lung stereotactic ablative radiotherapy (SABR)
por: Mark, Frances, et al.
Publicado: (2022)

Late metastatic presentation is associated with improved survival and delayed wide‐spread progression after ablative stereotactic body radiotherapy for oligometastasis
por: Chen, Xuguang, et al.
Publicado: (2021)

Developing a class solution for Prostate Stereotactic Ablative Body Radiotherapy (SABR) using Volumetric Modulated Arc Therapy (VMAT)
por: Murray, Louise J., et al.
Publicado: (2014)

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
por: Palma, David A., et al.
Publicado: (2020)

Stereotactic spine radiosurgery: Review of safety and efficacy with respect to dose and fractionation
por: Huo, Michael, et al.
Publicado: (2017)

The Judicious Use of Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy in the Management of Large Brain Metastases
por: Gutschenritter, Tyler, et al.
Publicado: (2020)

The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma
por: Barbour, Andrew B., et al.
Publicado: (2023)

Stereotactic ablative radiotherapy (SABR) as primary, adjuvant, consolidation and re-treatment option in pancreatic cancer: scope for dose escalation and lessons for toxicity
por: Goldsmith, Christy, et al.
Publicado: (2018)

Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR)
por: Dhaliwal, Inderdeep, et al.
Publicado: (2022)

Stereotactic ablative body radiotherapy (SABR) lung fractionations locally in the COVID-19 era and the impact on dosimetry, resources, early toxicities, and the environment
por: Phelps, Lyndsey, et al.
Publicado: (2021)

Risk for surgical complications after previous stereotactic body radiotherapy of the spine
por: Roesch, Johannes, et al.
Publicado: (2017)

Curing Operable Stage I Non-Small Cell Lung Cancer With Stereotactic Ablative Body Radiotherapy: The Force Awakens
por: Siva, Shankar, et al.
Publicado: (2016)

On the reduction of aperture complexity in kidney SABR
por: Gaudreault, Mathieu, et al.
Publicado: (2021)

To gate or not to gate - dosimetric evaluation comparing Gated vs. ITV-based methodologies in stereotactic ablative body radiotherapy (SABR) treatment of lung cancer
por: Kim, Joshua, et al.
Publicado: (2016)

Treatment-related neuroendocrine prostate cancer managed with partial stereotactic ablative radiotherapy (P-SABR) for long-term survival: a case series
por: Qi, Xin, et al.
Publicado: (2023)

Evaluation of Definitive Stereotactic Body Radiotherapy and Outcomes in Adults With Extracranial Oligometastasis
por: Poon, Ian, et al.
Publicado: (2020)

Systematic review of economic evaluations on stereotactic ablative radiotherapy (SABR) compared to other radiotherapy techniques or surgical procedures for early-stage non-small cell lung cancer
por: Maia, Fernando Henrique de Albuquerque, et al.
Publicado: (2023)

Clinical outcomes of MR-guided adrenal stereotactic ablative radiotherapy with preferential sparing of organs at risk
por: Schneiders, Famke L., et al.
Publicado: (2023)

Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis
por: Guckenberger, Matthias, et al.
Publicado: (2014)

Stereotactic ablative radiotherapy for the comprehensive treatment of 1–3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial
por: Olson, Robert, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_arrb3t428btqset259kf74o71r